[Form 4] Ardelyx, Inc. Insider Trading Activity
Laura A. Williams, listed as Chief Patient Officer and a director of Ardelyx, Inc. (ARDX), reported a non-derivative sale on 08/21/2025. The filing shows 6,261 shares of common stock were sold at $5.9317 per share under code S(1). The sale was executed pursuant to an automatic sell-to-cover tied to the vesting of restricted stock units to cover withholding taxes. After the transaction, Williams is reported to beneficially own 396,322 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025.
Laura A. Williams, indicata come Chief Patient Officer e membro del consiglio di Ardelyx, Inc. (ARDX), ha riportato una vendita non derivata in data 21/08/2025. La comunicazione indica che sono state vendute 6.261 azioni ordinarie al prezzo di $5,9317 per azione secondo il codice S(1). La vendita è stata eseguita tramite un meccanismo automatico di sell-to-cover collegato al vesting di restricted stock unit per coprire le imposte da trattenere. Dopo la transazione, a Williams risultano di beneficio 396.322 azioni. Il Modulo 4 è stato firmato da un procuratore il 25/08/2025.
Laura A. Williams, registrada como Chief Patient Officer y directora de Ardelyx, Inc. (ARDX), reportó una venta no derivada el 21/08/2025. La presentación muestra que se vendieron 6.261 acciones ordinarias a $5,9317 por acción bajo el código S(1). La venta se ejecutó mediante un mecanismo automático de sell-to-cover vinculado al vesting de unidades restringidas para cubrir impuestos retenidos. Tras la operación, Williams posee de forma beneficiaria 396.322 acciones. El Formulario 4 fue firmado por un apoderado el 25/08/2025.
Laura A. Williams는 Ardelyx, Inc. (ARDX)의 Chief Patient Officer이자 이사로 등재되어 있으며, 2025-08-21에 비파생(non-derivative) 주식 매각을 신고했습니다. 신고서에 따르면 보통주 6,261주가 주당 $5.9317에 코드 S(1)로 매도되었습니다. 이 매도는 제한조건부주식(RSU)의 베스팅에 연동된 자동 sell-to-cover 방식으로 원천징수세를 충당하기 위해 이루어졌습니다. 거래 후 Williams는 총 396,322주를 사실상 보유한 것으로 보고되었습니다. Form 4는 2025-08-25에 법정대리인이 서명했습니다.
Laura A. Williams, inscrite comme Chief Patient Officer et administratrice d'Ardelyx, Inc. (ARDX), a déclaré une vente non dérivée le 21/08/2025. Le dossier indique que 6 261 actions ordinaires ont été vendues au prix de $5,9317 par action sous le code S(1). La vente a été effectuée via un mécanisme automatique de sell-to-cover lié au vesting d'unités d'actions restreintes pour couvrir les impôts à retenir. Après la transaction, Williams détient à titre bénéficiaire 396 322 actions. Le Formulaire 4 a été signé par un mandataire le 25/08/2025.
Laura A. Williams, aufgeführt als Chief Patient Officer und Direktorin von Ardelyx, Inc. (ARDX), meldete am 21.08.2025 einen nicht-derivativen Verkauf. Die Einreichung weist aus, dass 6.261 Stammaktien zu je $5,9317 unter dem Code S(1) verkauft wurden. Der Verkauf erfolgte im Rahmen eines automatischen Sell-to-Cover, das mit dem Vesting von Restricted Stock Units verknüpft ist, um Quellensteuern zu decken. Nach der Transaktion besitzt Williams wirtschaftlich 396.322 Aktien. Das Formular 4 wurde am 25.08.2025 von einem Bevollmächtigten unterzeichnet.
- Transaction documented and compliant with Section 16 reporting and shows use of automatic sell-to-cover for RSU tax withholding
- None.
Insights
TL;DR: Routine sell-to-cover of vested RSUs indicates standard tax withholding, not a discretionary sale by the reporting officer.
The Form 4 documents an automatic sell-to-cover related to RSU vesting, which is a common administrative action to satisfy tax withholding obligations. The transaction code S(1) and the filing note clarify the shares were sold solely to cover taxes rather than for liquidity or trading purposes. The reported remaining beneficial ownership of 396,322 shares provides context for the officer's stake but does not alone imply a change in control or material shift in alignment with shareholders.
TL;DR: Small, routine disposal; transaction size is immaterial relative to typical insider holdings and company market cap.
The sale of 6,261 shares at $5.9317 per share is explicitly described as automatic sell-to-cover on RSU vesting. Such transactions are administrative and typically categorized as neutral for valuation or governance assessments. The remaining beneficial ownership figure is stated, enabling tracking of insider holdings over time. No derivative transactions or additional dispositions are reported in this filing.
Laura A. Williams, indicata come Chief Patient Officer e membro del consiglio di Ardelyx, Inc. (ARDX), ha riportato una vendita non derivata in data 21/08/2025. La comunicazione indica che sono state vendute 6.261 azioni ordinarie al prezzo di $5,9317 per azione secondo il codice S(1). La vendita è stata eseguita tramite un meccanismo automatico di sell-to-cover collegato al vesting di restricted stock unit per coprire le imposte da trattenere. Dopo la transazione, a Williams risultano di beneficio 396.322 azioni. Il Modulo 4 è stato firmato da un procuratore il 25/08/2025.
Laura A. Williams, registrada como Chief Patient Officer y directora de Ardelyx, Inc. (ARDX), reportó una venta no derivada el 21/08/2025. La presentación muestra que se vendieron 6.261 acciones ordinarias a $5,9317 por acción bajo el código S(1). La venta se ejecutó mediante un mecanismo automático de sell-to-cover vinculado al vesting de unidades restringidas para cubrir impuestos retenidos. Tras la operación, Williams posee de forma beneficiaria 396.322 acciones. El Formulario 4 fue firmado por un apoderado el 25/08/2025.
Laura A. Williams는 Ardelyx, Inc. (ARDX)의 Chief Patient Officer이자 이사로 등재되어 있으며, 2025-08-21에 비파생(non-derivative) 주식 매각을 신고했습니다. 신고서에 따르면 보통주 6,261주가 주당 $5.9317에 코드 S(1)로 매도되었습니다. 이 매도는 제한조건부주식(RSU)의 베스팅에 연동된 자동 sell-to-cover 방식으로 원천징수세를 충당하기 위해 이루어졌습니다. 거래 후 Williams는 총 396,322주를 사실상 보유한 것으로 보고되었습니다. Form 4는 2025-08-25에 법정대리인이 서명했습니다.
Laura A. Williams, inscrite comme Chief Patient Officer et administratrice d'Ardelyx, Inc. (ARDX), a déclaré une vente non dérivée le 21/08/2025. Le dossier indique que 6 261 actions ordinaires ont été vendues au prix de $5,9317 par action sous le code S(1). La vente a été effectuée via un mécanisme automatique de sell-to-cover lié au vesting d'unités d'actions restreintes pour couvrir les impôts à retenir. Après la transaction, Williams détient à titre bénéficiaire 396 322 actions. Le Formulaire 4 a été signé par un mandataire le 25/08/2025.
Laura A. Williams, aufgeführt als Chief Patient Officer und Direktorin von Ardelyx, Inc. (ARDX), meldete am 21.08.2025 einen nicht-derivativen Verkauf. Die Einreichung weist aus, dass 6.261 Stammaktien zu je $5,9317 unter dem Code S(1) verkauft wurden. Der Verkauf erfolgte im Rahmen eines automatischen Sell-to-Cover, das mit dem Vesting von Restricted Stock Units verknüpft ist, um Quellensteuern zu decken. Nach der Transaktion besitzt Williams wirtschaftlich 396.322 Aktien. Das Formular 4 wurde am 25.08.2025 von einem Bevollmächtigten unterzeichnet.
FAQ
What did Laura A. Williams report on Form 4 for ARDX?
Why were the ARDX shares sold by the reporting person?
How many ARDX shares does Laura A. Williams beneficially own after the transaction?
Who signed the Form 4 for Laura A. Williams and when was it signed?
Was this Form 4 filed by one reporting person or multiple filers?
